- Repligen’s $1.5B buy for BioLife; BeOne’s $300M US expansionPlus, news about Lonza, Bachem and Samsung Biologics. 🤝 Repligen to acquire BioLife Solutions: Repligen will pay around $1.5 billion for cell processing service supplier BioLife, 36% of which w…Endpoints · 1d ago↗ source
- STAT+: FDA is urged by advocacy group to ban DTC prescription drug adsA leading advocacy group petitioned the FDA to ban direct-to-consumer advertising of prescription medicines.STAT · 1d ago↗ source
- Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 dataWith weight loss topping 20% at 80 weeks in the Phase 3 TRIUMPH-2 and TRIUMPH-3 trials, Eli Lilly plans to file for retatrutide’s approval in the first quarter of 2027. Previously a filing was expe…